GLP-1 Side Effects Compared

Based on clinical trial data, tirzepatide (Mounjaro/Zepbound) consistently shows lower rates of nausea, vomiting, and diarrhea compared to semaglutide at comparable efficacy. However, individual responses vary — some patients tolerate semaglutide perfectly while struggling with tirzepatide.

Most gastrointestinal side effects peak during the first 4-6 weeks (during dose titration) and resolve by 8-12 weeks. Patients who follow the prescribed gradual dose escalation schedule experience milder and shorter-duration side effects.

Hair thinning (telogen effluvium) is associated with rapid weight loss from any cause, not specifically with GLP-1 drugs. It typically appears 2-4 months after significant weight loss begins and resolves within 6-12 months. Adequate protein and micronutrient intake can minimize this effect.

The vast majority of side effects are uncomfortable but not dangerous. Rare serious risks include pancreatitis (~0.1-0.3%), gallbladder disease (~1-2%), and allergic reactions. These require prompt medical attention but affect a small minority of patients.

Not necessarily. Side effects indicate that the GLP-1 receptor is being activated, but therapeutic benefit (weight loss, glucose control) doesn't require experiencing side effects. Many patients achieve excellent results with minimal or no symptoms.

Yes. Ondansetron (Zofran) and other anti-emetics are commonly prescribed alongside GLP-1 therapy during the titration period. Discuss options with your healthcare provider if nausea is significantly impacting your quality of life.